Compare Gilead Sciences, Inc. (GILD) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Trip.com Group Ltd — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Trip.com Group Ltd trades at $38.7 (market cap $24.30B). The key difference: Gilead Sciences, Inc. is far larger — about 7.5× Trip.com Group Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Trip.com Group Ltd for 79 Days on average.
| GILD | TCOM | |
|---|---|---|
Market Cap | $182.09B | $24.30B |
Volume | 4,960,247 | 1,885,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $78.96 |
52-Week Low | $116.74 | $37.96 |
Typical Hold Time | 111 Days | 79 Days |
Enterprise Value | $205.15B | $16.46B |
Dividend Yield | 2.23% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Trip.com (TCOM) trades at $37.96, down 0.78% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 36.9% net income margin and trades at a low P/E of 7.36. Recent Q2 2026 earnings beat expectations, yet regulatory pressures and a challenging travel environment create headwinds. Analyst consensus remains strongly bullish with a $56.64 price target, indicating significant upside potential from current levels.
The outlook for TCOM balances strong earnings growth and attractive valuation against regulatory risks and market volatility. Investment opportunity lies in its dominant travel platform and international expansion, but investors face risks from antitrust penalties and competitive pressures. The stock's current discount to analyst targets presents a potential value opportunity if execution remains solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
